Inotiv, Inc. Bolsters Pathology Services with Acquisition of Histion, LLC
On April 25, 2022, Inotiv, Inc. (NASDAQ: NOTV) announced the acquisition of Histion, LLC, as part of its strategy to expand specialized pathology services. This acquisition enhances Inotiv's histology operations in the plastics and medical device sectors, supporting its previously announced expansion of surgical models and medical device testing services in Fort Collins, CO. Chief Operating Officer Greg Beattie emphasized the benefits of Histion's expertise in improving client support, while Histion's President Peggy Lalor expressed enthusiasm about integrating their pathology services with Inotiv's offerings.
- Acquisition of Histion expands Inotiv's specialized pathology services.
- Enhancement of histology operations supports growth in plastics and medical device pathology.
- Integration of Histion's expertise will improve client study design and evaluation of medical device safety.
- None.
WEST LAFAYETTE, Ind., April 25, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the acquisition of Histion, LLC (“Histion”), effective April 25, 2022. The acquisition is a strategic element of the Company’s expansion of its specialized pathology services.
“The acquisition of Histion extends our histology operations into highly-specialized plastics and medical device pathology,” said Greg Beattie, Chief Operating Officer, Discovery and Development Services at Inotiv. “This acquisition will also support the previously announced expansion of our surgical model and medical device testing services in Fort Collins, CO, and will accelerate the development of these services and our future expansion plans.”
Beattie continued, “We have a valued, longstanding history of working with Histion, and are confident that the addition of Histion’s expert team will enable us to better assist our clients in study design and the effective evaluation of the safety and efficacy of medical devices across a very broad array of therapeutic indications.”
Peggy Lalor, President and Founder of Histion, added, “We are thrilled to be part of Inotiv’s growth. Integrating our pathology expertise with the comprehensive services at Inotiv will allow us to provide more complete and flexible solutions to our clients.”
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations |
| Inotiv, Inc. | The Equity Group Inc. |
| Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA |
| (765) 497-8381 | (212) 836-9614 |
| btaylor@inotivco.com | kahl@equityny.com |
| Devin Sullivan | |
| (212) 836-9608 | |
| dsullivan@equityny.com |
FAQ
What is the significance of Inotiv's acquisition of Histion, LLC?
When was the acquisition of Histion by Inotiv announced?
How does the acquisition of Histion impact Inotiv's services?
What are the expected benefits of Inotiv acquiring Histion?
